Evaluation of the cytotoxic activity of Tamarix articulata and its anticancer potential in prostate cancer cells

Abdullah M. Alnuqaydan1*, Abdulmajeed G. Almutary1, Ohood Y. Alshehri2, Hanan Ali Henidi3, Abdullah M. Alajlan4, Abdullah Al Tamim4, Abdullah Alowaifeer4, Mohd Younis Rather4, Bilal Rah11* ©

1Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Buraidah, Saudi Arabia.
2Department of Biochemistry, College of Medicine, Al-Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
3Research Department, Health Sciences Research Center, Princess Nourah Bint Abdul Rahman University, Riyadh, Saudi Arabia.
4Reference Laboratory for Food Chemistry, Saudi Food Drug Authority SFDA, Riyadh, Saudi Arabia.
5Postgraduate Department of Pharmacology, Government Medical College, Srinagar, India.

ARTICLE INFO
Received on: 24/07/2021 Accepted on: 25/10/2021 Available Online: 05/02/2022

Key words:
Tamarix articulata, plant extracts, metastasis, anticancer, prostate cancer, apoptosis, cell motility, cell invasion.

ABSTRACT
Anticancer drugs induce cell death mechanism in tumor cells by various modes, which include apoptosis, autophagy, and necroptosis. However, they become ineffective when tumor cells enter metastasis. Thus, searching for plant-based extracts/compounds to curtail metastasis is extremely important. This study aims to evaluate the anticancer potential of Tamarix articulata (TA) extract against prostate cancer cells. MTT, Brd U, and trypan blue assays were carried out to evaluate the cell viability. Terminal Transferase dUTP Nick End Labeling assay was carried out to determine apoptotic cells. Clonogenic, wound-healing, and Boyden chamber assay was conducted to evaluate the anticlonogenic, antimotility, and anti-invasive potential of TA. Zymography and immunoblotting were carried out to check the activity and expression of metalloproteases and proteins associated with metastasis. Our results demonstrated that TA extract significantly inhibits cell viability and clonogenic property and displays IC50 values in the 245–289 µg/ml range. TA extract significantly abrogates the motility and invasive property of LnCaP cells in a dose-dependent manner. Mechanistically, TA extracts downregulate the expression of phosphoinositide 3-kinase-protein kinase B (PI3K-Akt), transforming growth factor-beta-Sma genes and the Drosophila Mad, mothers against decapentaplegic protein 2/3 (TGF-β-SMAD2/3), and matrix metalloproteinases-2/9 (MMP-2/9) with concomitant upregulation of tissue inhibitor of metalloproteinase 1 (TIMP1) expression in LnCaP cells. Additionally, we observed a dose-dependent downregulation of snail and vimentin with the upregulation of E-cadherin protein expression in LnCaP cells. TA extract exhibits an antiproliferative effect and abrogates cell motility and invasion by downregulating PI3K-Akt, TGF-β-SMAD2/3, MMP-2/9, snail, and vimentin with concomitant upregulation of E-cadherin and TIMP1 expression in prostate cancer cells.

INTRODUCTION
Tumor metastasis is a series of events governed by complex mechanisms that are initiated by the detachment of tumor cells, followed by invasion, migration, endothelial cell adhesion, and finally reestablishment of tumor growth at distant sites (Roodman, 2004). Most tumor cells undergo apoptosis by chemotherapeutic drugs (Strasser and Vaux, 2020). Some cells sustain chemotherapeutic drugs and often evade cell death mechanisms due to the accumulation of oncogenic mutations, which enhance tumor cell growth (Strasser and Vaux, 2020). These resistant cells can successfully advance metastatic dissemination to distant sites and pose a serious challenge to the current chemotherapeutics regimes (Valastyan and Weinberg, 2011). Despite significant advances being made in the conventional therapeutics of cancer, tumor metastasis is still a major problem (Baudino, 2015; Valastyan and Weinberg, 2011). Owing to the absence of any therapeutics against metastasis, most cancer-related deaths occur due to metastasis (Mehlen and Puisieux, 2006). It is one of the leading metastasis-associated deaths in Western countries; approximately 50% of prostate cancer patients
clinically present with bone metastasis (Stavridi et al., 2010). The therapeutic interventions for prostate cancer are surgery (radical prostatectomy), radiotherapy, and adjuvant chemotherapy (Suardi et al., 2014). The bone-associated metastasis in prostate cancer is extremely resistant to radiotherapy and to the present regimen of ablation of androgen therapy (Suardi et al., 2014). Owing to the development of androgen-independent prostate cancer, relapse is inevitable approximately after 18 months in prostate cancer metastasis. This indicates that there is no therapeutic option for metastatic prostate cancer patients thereafter (Zhang et al., 2017). For this reason, new therapeutics are urgently required to treat metastatic prostate cancer.

Various cancers, including prostate cancer, are less evident in the Arab population compared to Western societies (Hilal et al., 2015). This may be due to the difference in prostate cancer screening, poor counseling for prostate-specific antigen (Arafà and Rabah, 2017), low androgenic factors with high polyunsaturated fats in Mediterranean foods, which maintains the testosterone level under a certain level (Al-Abdin and Al-Beeshi, 2018), and dietary advantages of plants having a great medicinal value (Ito, 2014).

Ever since ancient times, plants have been used to treat numerous ailments (Kaur et al., 2011). Owing to the presence of secondary metabolites such as alkaloids, phenolics, and terpenoids, which act as defense mechanisms against both abiotic and biotic stresses, these compounds have promising medicinal importance (Verma and Shukla, 2015). One such plant in the deserts of Saudi Arabia containing a wide variety of secondary metabolites is Tamarix articulata (TA) (Alnuqaydan and Rah, 2019). This plant belongs to the family Tamaricaceae and is a halophytic plant growing in extremely harsh and arid conditions in the deserts of Saudi Arabia (Said et al., 2018). Commonly called Athal in the Arabic language, TA has been extensively used as folk medicine by the Tafilalet, a tribal people in the southeastern area of Morocco. TA is a halophytic plant growing in extremely harsh environmental conditions. It exhibits promising biological activities such as antioxidant, anti-diabetic, hypolipidemic, antibacterial, and hepatoprotective activities (Alnuqaydan and Rah, 2019, 2020; Bencherif et al., 2015; Hebi et al., 2017, 2018; Said et al., 2018). The plant is woody and possesses great medicinal value. Traditionally, the plant is used to treat various ailments such as gastrointestinal diseases, skin diseases, heart diseases, and other ailments (Said et al., 2018). The phytochemical analysis of the methanolic extract of TA by liquid chromatography with tandem mass spectrometry (LC-MS) analysis reveals the identification of more than 200 compounds. The key phytochemicals identified from the methanolic extract of TA by LC-MS were reported to exhibit anticancer activities against various cellular models. Crude extracts of the plant have been reported to exhibit anticancer properties by inhibiting cell viability in various types of cancer cells in other parts of the world (Shaalan et al., 2018). Consistent with the preliminary reports, our group also revealed that the methanolic extract of TA demonstrates promising antiproliferative activity against breast, colorectal, and hepatocellular carcinoma cells (Alnuqaydan and Rah, 2020).

However, no data are yet available for the antimetastatic activity of TA extract. For this reason, the current study aims to evaluate the antiproliferative and antimetastatic activities of TA extract against prostate cancer cells and to investigate the possible underlying inhibitory mechanism against prostate cancer cells.

**MATERIALS AND METHODS**

**Collection of plant material and preparation of extract**

The TA plant material is scientifically well-characterized and belongs to clade: angiosperms, order: Caryophyllales, family: Tamaricaceae, genus: Tamarix, and species: Tamarix articulata, which was collected in August 2019 from the deserts of Qassim province in the Kingdom of Saudi Arabia. A methanolic extract derived from the dry leaves was prepared as per the standard protocol published in our previous work (Alnuqaydan and Rah, 2020). After collection, the TA parts were first air-dried in the shade to remove the moisture completely. Using sharp blades, TA was chopped into small pieces, followed by grinding in a kitchen blender to produce a fine powder. After weighing, 12 g of TA powder was added to 300 ml of 100% methanol and constantly stirred with a magnetic bead for 5 days at room temperature. The mixture obtained was first filtered through cheesecloth to remove the bulk, followed by filtration through a Whatman filter paper in an autoclaved glass beaker. The methanol (solvent) was completely evaporated from the plant extract mixture in a glass beaker by keeping the temperature of the hot plate at 45°C to avoid the degradation of heat-labile compounds. After the complete evaporation of the solvent, the fine powder of residue left in the glass beaker was collected and stored at 4°C in stored vials for future experiments to evaluate the biological activities of the TA.

**Sample preparation**

Plant metabolites from TA were extracted as described by previously published work (Alnuqaydan and Rah, 2020). Briefly, 50 mg of plant material was weighed into an Eppendorf tube, and 1 ml of methanol was added, vortexed for 30 seconds, and then centrifuged for 15 minutes at 5,000 rpm. After centrifugation, 200 µl of the supernatant was diluted fivefold with HPLC grade acetone and then filtered through a 0.2 μm filter. Afterward, the metabolic filtrate was transferred into an LC vial for analysis.

**LC-MS metabolomic analysis and data processing**

The analysis was carried out on an LC-MS consisting of an ACQUITY UPLC I-Class System (Waters Technologies, USA) coupled to a 6,500 Qtrap (AB Sciex, Canada). The chromatographic separation was carried out on a Zorbax XDB C18 column (2.1 × 150 mm. 3.5 μm) (Agilent, USA) and kept at 40°C with a flow rate of 300 µl/minute. The mobile phase consisted of A (0.1% formic acid in HPLC grade water) and B (0.1% formic acid in HPLC grade acetone). The linear gradient elution was as follows: 2% B (from 0 to 2), 95% B (from 2 to 24), 95% B (held for 2 minutes), and then 4 minutes equilibration time. Electrospray ionization mass spectra (MS) were acquired in the positive (ES +), with an electrode voltage of 5500 V. The declustering potential was set at 90 V, and the entrance potential was 10 V. Nitrogen was used as curtain gas (30 psi) and nebulizer gas on the MS. Spectra were collected with a mass range of 100–900 m/z. Data files from the LC were converted to MZxml format using MS Convert (ProteoWizard 3.0.20270). Analysis of the data was conducted using MZmine software (version 2.53). After importing the data into MZmine, a minimum intensity cutoff of 1,000 was applied, and the retention time was adjusted with a tolerance of 0.2 minutes. An adjusted peak was then aligned.
into one mass list to facilitate identification and comparison. The Kyoto encyclopedia of genes and genomes database software was used to identify compounds of interest in the finalized list based on m/z with a tolerance of 30 ppm.

**Culturing of cells and treatments**

The cellular models of prostate cancer cells (PC-3, LnCaP, DU 145, C4-2b, and VCaP) were ordered and purchased from the American Type Culture Collection (ATCC); however, benign prostate hyperplasia (BPH) cells were procured from Sigma (Merck). All the purchased cell lines were cultured in their respective cell culture media [Roswell Park Memorial Institute-1640 (#11875101) and Minimal Essential Medium (#31095029)] in a 5% CO₂ incubator. The cell culture medium procured from Thermo Fisher Scientific was supplemented with L-glutamine and phenol red. Externally, culture media were added with 1% penicillin-streptomycin (#15140122) and 10% fetal bovine serum (#16000044) procured from Thermo Fisher Scientific. All the cell lines obtained from ATCC were regularly checked for all Mycoplasma contaminations.

**Chemicals, reagents, and antibodies**

- Dimethyl sulfoxide (DMSO, #D2650), phenylmethylsulfonyl fluoride (PMSF, #52332), propidium iodide (PI, #4170), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, #M5655), triton X-100 (#T8787), paraformaldehyde (#158127), 4',6-diamidino-2-phenylindole dihydrochloride (DAPI, #D8417), and trypan blue (#T6146) were ordered and purchased from Sigma Aldrich. However, primary antibodies were ordered and bought from cell signaling technology, these being β-actin (#4970), phosphoinositide 3-kinase-protein kinase B (PI3K-p110α) (#4249S), protein kinase B (Akt) (#4691S), p-Akt-Ser473 (#4060), transforming growth factor-beta (TGF-β) (#3711S), Smα genes and the Drosophila Mad, mothers against decapentaplegic protein 2 (SMAD2) (#5339S), SMAD3 (#9523S), tissue inhibitor of metalloproteinase 1 (TIMP1) (#8946S), matrix metalloproteinases-2 (MMP-2) (#40994S), E-cadherin (#14472S), snail (#3879S), vimentin (#5741S), and MMP-9 (#13667S). From Santa Cruz Biotechnology, secondary antibodies, namely anti-rabbit IgG (SC-2359) and anti-mouse IgG (SC-2005), coupled with enzyme horseradish peroxidase (HRP) were procured.

**Preparation of TA stock solution**

The TA stock solution in DMSO (100 mg/ml) was prepared, aliquoted, and stored in autoclaved microcentrifuge tubes (1.5 ml) at −20°C. At the time of the experiment, stock concentration was diluted with culture media to prepare a working concentration (10–10,000 µg/ml) for exposing prostate cancer cells to varying doses of TA extract.

**Cell proliferation assay/cell cytotoxicity assay**

The proliferation of prostate cancer cells was determined by the most used MTT assay (Rah et al., 2012). Briefly, a panel of prostate cancer and transformed cells (PC-3, LnCaP, DU 145, and BPH) were subjected to harvesting and seeded at a density of 2×10⁴ cells in each well of a 96-well plate. The seeded cells were exposed to various doses of TA extract (10–10,000 µg/ml) along with DMSO control. After incubation lasting for 24 hours in a 5% CO₂ incubator, cells were flooded with 20 µl of 2.5 mg/ml MTT dye and incubated for 3 hours, at 5% CO₂ incubator at 37°C. After incubation, it is necessary to remove the media containing MTT dye and add DMSO to dissolve formazan crystals which are formed by reducing the tetrazolium salts by dehydrogenase and reductase enzymes of live cells. These were formed when cells were incubated in MTT dye. The purple-colored solution obtained after proper mixing or gentle shaking of the 96-well plate was measured at 570 nm to record absorbance. The IC₅₀ value, which is the concentration of a TA extract to kill half of the cell population, is calculated by using the formula:

\[
\% \text{ cell survival} = \frac{\text{absorbance of compound} - \text{absorbance of control}}{\text{absorbance of blank}} \times 100
\]

**Colony formation assay**

LnCaP cells 1×10⁴ plated in the 6-well plates were treated with varying concentrations of TA extract (67.5, 125, 250, and 500 µg/ml) along with control DMSO and staurosporine (11.663 µg/ml) (Sinha et al., 2013). The treated cells were incubated in 5% CO₂ at 37°C for 5 days. Next, the medium was discarded, and the treated cells were washed with precooled PBS. Following this, the cells were fixed in ice-cold methanol for 20 minutes and then stained with 0.5% crystal violet solution for about 15 minutes. The cellular colonies stained in each well of the 6-well plate were photographed with a phase-contrast microscope, and the cells in each colony were counted.

** Scratch motility (wound-healing) assay**

Briefly, prostate cancer cells (LnCaP) were harvested from the culture flask, followed by seeding of 5.5 × 10⁵ cells in each well of the 6-well plate (Zilla et al., 2014). After overnight incubation in a 5% CO₂ incubator at 37°C, a complete mat of the monolayer was formed of the cells. In the middle of each well, a scratch was made with a sterile 200 ul microtip to create a wound. The 6-well plate with serum-free media was employed to wash out detached cells while creating a wound. After clearing detached cells, wound-created wells were exposed to varying concentrations of TA extract, that is, 67.5, 125, 250, and 500 µg/ml, in the presence of untreated control and positive control camptothecin 2 µM for 24 hours. Next, the cells were analyzed under a microscope, and then photographs were taken of areas where the wound was created at 0 hour. The percentage of wound closure was measured by using the formula as follows:

\[
\% \text{ of wound closure} = \frac{[1-(\text{area of wounding after 24 hours}/\text{area of the wound at 0 hour})]}{100}
\]

**Transwell Boyden chamber invasion assay**

Briefly, 1.25 × 10⁴ LnCaP cells were harvested, counted, and added uniformly to the culture medium without serum in the upper insert of the Transwell Boyden chamber plate and subsequently subjected to varying doses of TA extract (67.5, 125, 250, and 500 µg/ml). This occurs in the presence of control (untreated) and camptothecin 2 µM as a positive control. The lower chamber was filled with 10% serum-containing media as the chemoattractant. Resuspended cells exposed to varying concentrations of TA extract tried to move towards the lower chamber containing 10% serum media. After 24 hours, the porous Matrigel-coated polycarbonate insert membrane was removed, and
the attached cell inside the insert was completely wiped off with a swab of cotton. These cells that adhered to the bottom outside of the upper insert were fixed in precooled methanol for 15 minutes. This was followed by staining the cells with 0.25% crystal violet solution in PBS. Then this stained porous biological membrane was put under a microscope to examine cells and subsequently photographed. The cells which can cross the membrane were photographed and counted under a phase-contrast microscope.

Gelatin zymography

Prostate (LnCaP) cancer 5 × 10^5 cells were harvested and plated in a 6-well plate as carried out previously (Rah et al., 2012). Cells were exposed to varying concentrations of TA extract (67.5, 125, 250, and 500 µg/ml) along with control DMSO and camptothecin (2 µM) as a positive control for 24 hours. The conditional media obtained from each treated well along with untreated control and positive control were collected in separate autoclaved 2 ml microcentrifuge tubes. Each sample was subjected to protein estimation by the standard Bradford method. The equal protein concentration of all samples was mixed with loading dye. The samples were loaded in the wells of SDS-PAGE gel containing 0.1% gelatin, and the gel could resolve by setting the voltage initially at 80 V and after samples entering the resolving gel set the voltage at 100 V for 3 hours at 4°C. The resolved gelatin gel was washed with a 2% Triton X-100 buffer to remove SDS. The gel with incubation buffer was incubated to renature the MMP for 24 hours at 37°C. Following this, the gel with Coomassie brilliant blue solution was stained for 1 to 2 hours, followed by distaining of gel with a mild destaining solution to ensure that clear bands appeared. The gelatinase activity was determined by analyzing clear transparent bands against the dark blue background after Coomassie brilliant blue staining.

Immunoblotting

Briefly, 50 × 10^4 cells (LnCaP) were plated in each well of the 6-well plate, and they were allowed to adhere overnight to the bottom surface of the well in a 5% CO_2 incubator at 37°C. The attached LnCaP cells were exposed to varying doses of TA extract (67.5, 125, 250, and 500 µg/ml) along with the DMSO vehicle (Rasool et al., 2017). After 24 hours, the treated cells were gently washed with precooled PBS, scraped, and harvested in a sterile microcentrifuge tube. 500 µl of lysis buffer, which contained PMSF and protease cocktail inhibitor, was added, and cells repeatedly agitated intermittently for 10 seconds and kept on ice for 2–3 minutes. This was carried out five times to ensure complete lysis. The cell lysate solution was centrifuged at a speed of 12,000 g for 15 minutes at 4°C to collect the supernatant. Using the Bradford method, the collected supernatant was subjected to the process of estimating protein concentration. 15–20 µg protein from each TA exposed cell sample was calculated for loading in SDS-PAGE gel and resolving the gel. This followed the protocol mentioned in the above reference. Then SDS-PAGE gel was transferred onto the PVDF membrane followed by incubation of this membrane in a blocking solution containing 5% fat-free milk. This served to block nonspecific sites. The PVDF membrane was incubated with primary antibody solution for 3–4 hours at room temperature or overnight at 4°C. Subsequently, the PVDF membrane was washed with TBST 6 times followed by incubation with secondary antibody labeled with enzyme HRP for 1 hour 30 minutes at room temperature. After incubation was completed, the PVDF membrane was washed with TBST 6 times, and each washing lasted 5 minutes. After washing, cleaning, and drying the PVDF membrane, immunoreactive substances enhanced the process of chemiluminescence to detect the bands on the PVDF membrane. The chemiluminescent signal on the PVDF membrane with the X-ray films was captured after proper exposure under dark conditions or with inbuilt chemiluminescent gel doc.

Cell proliferation (Brd U) assay

Antiproliferative activity of TA extract against a panel of prostate cancer cell lines was evaluated by using colorimetric method Brd U cell proliferation ELISA kit (Abcam #Ab126556). Briefly, 2 × 10^4 cells were plated in each well of the 96-well plate overnight. After adhering properly to the bottom surface of the well, cells were exposed to varying doses (10–10,000 µg/ml) of TA extract for 24 hours at 37°C in 5% CO_2 incubator in triplicate. After the exposure of cells to TA extract, as per the manufacturer’s instruction, cells were incubated with Brd U for 2 hours at 37°C to incorporate Brd U in DNA. The cells were fixed, permeabilized, and desaturated, followed by gentle washing and aspiration. Cells were incubated with anti-Brd U monoclonal antibody for 1 hour at room temperature. After proper incubation and removal of unbound fraction of anti-Brd U from wells by gently washing and aspiration, wells were incubated with TMB solution containing enzyme-labeled goat anti-mouse antibody. After the formation of color by enzymatic reaction indicates the cell proliferation, the stop solution was added, and absorbance was recorded immediately by using a multplate reader.

Cell counting (trypan blue) assay

Briefly, 5 × 10^4 prostate cancer cells were plated in each well of a 24-well plate. After properly adhering to the bottom surface, cells were exposed to dose-dependent (10–10,000 µg/ml) treatment with TA extract for 24 hours at 37°C in 5% CO_2 incubator. After the completion of the time point, the treated cells were harvested and stained with trypan blue dye. The dead cells were stained with trypan blue; however, live cells were easily counted by trypan blue exclusion test.

Phase-contrast microscopy

Phase-contrast microscopy was carried out to detect the change in cellular morphology of prostate cancer cells after dose-dependent treatment with TA extract for 24 hours. Briefly, 0.5 × 10^6 were seeded per well of a 6-well plate and exposed to different doses of TA extract for 24 hours. After the completion of treatment, cells were analyzed by a phase-contrast microscope inbuilt with a camera to detect any change in the cellular morphology of cells.

Detection of apoptosis by Terminal Transfserase dUTP Nick End Labeling (TUNEL) assay

Detection of the apoptotic population of prostate cancer cells after exposure to varying doses of TA extract for 24 hours was detected by the TUNEL assay apoptosis detection kit (Roche). After seeding, the LnCaP cells at a density of 5 × 10^4 per well on the sterile coverslips placed within the wells of the 6-well plate were incubated overnight in 5% CO_2 at 37°C. After the completion of
exposure time (24 hours) to various doses of TA extract (67.5, 125, 250, and 500 µg/ml), cells grown on the coverslips were processed for fixation (4% paraformaldehyde) and permeabilization (4% Triton X-100) at room temperature for 10 minutes. Next, cells grown on the coverslips were incubated with a mixture of terminal deoxynucleotidyl transferase (TdT) and biotin-dUTP for 1 hour to label the blunt ends of double-stranded DNA breaks independent of substrate in cells undergoing apoptosis, followed by 30 minutes incubation with an avidin-FITC solution in the dark to tag the apoptotic cells which were green fluorescent compound for the detection and quantification. Subsequently, DAPI solution was added to stain the nucleus, which appears blue in color. After the completion of TUNEL staining, coverslips containing cells were put onto the clean grease-free glass slide and sealed the edges with nail polish to avoid any dryness of the slide. The glass slides were analyzed by confocal microscope (Zeiss LSM 710 META, Germany) for the detection of TUNEL-positive cells.

Statistical analysis

All the experiments in the current study were carried out at least three or more times. Statistical analysis of all the independent experiments was conducted by using GraphPad Prism software. The results obtained were expressed as mean ± SEM. All the experiments were analyzed using one-way analysis of variance. Statistical significance was expressed as p-value, wherein the p-value of less than or equal to 0.05 was significant.

RESULTS

TA extract exhibits promising antiproliferative activity, induces apoptosis, and abrogates clonogenic properties in prostate cancer cells

We proposed to examine the antiproliferative potential of TA extract on the cellular growth of prostate cancer (PC-3, DU 145, LnCaP, C42B, and VCaP) cells and normal BPH cell line. The antiproliferative potential of TA extract was analyzed using the MTT assay to determine the percentage of cell viability. Our MTT results showed that TA extract could start inhibiting prostate cancer cell growth at a dose of 10 µg/ml. Using GraphPad Prism software to evaluate the IC\textsubscript{50} value of TA extract against a panel of prostate tumor cells, we observed the IC\textsubscript{50} values of TA extract are 245, 248, 256, 289, and 273 µg/ml.

Figure 1. TA extract inhibits the cell proliferation of prostate cancer cells. (a) MTT assay showed a dose-dependent inhibition of prostate cancer cell panel (PC-3, LnCaP, DU 145, C42B, and VCaP) and normal transformed prostate cells (BPH) upon treatment with varying doses (1, 10, 100, 1,000, and 10,000 µg/ml) of TA extract for 24 hours. (b) Brd U incorporation assay to determine cell proliferation of prostate cancer cells after exposure to different doses of TA extract for 24 hours. (c) Trypan blue exclusion assay to determine the cell viability of prostate cancer cells after varying treatments of TA extract for 24 hours. (d) Phase-contrast microscopy to analyze changes in cellular morphology of prostate cancer cells (LnCaP) after treatment with different doses of TA extract (67.5, 125, 250, and 500 µg/ml) for 24 hours. The representation of data is the mean value of ±SE of three or more than three independent experiments with statistical significance equal to *p < 0.05; **p < 0.01.
µg/ml against LnCaP, PC-3, DU 145, C42B, and VCaP cells, respectively (Fig. 1a). Intriguingly, we observe a significantly high IC$_{50}$ value (9,541 µg/ml) of normal BPH cells when exposed to varying doses of TA extract. This indicates that TA extract attenuates prostate tumor cell growth specifically and exhibits a safe level of toxicity against normal transformed cells (BPH). To further confirm the antiproliferative potential of TA extract, we carried out Brd U incorporation and trypan blue exclusion assays. Our results showed that a significant reduction of Brd U incorporation (a thymidine analog) (*p < 0.05; **p < 0.01) (Fig. 1b) and viability of cells by trypan blue exclusion assay (*p < 0.05; **p < 0.01) (Fig. 1c) were observed after prostate cancer cells were exposed to varying doses of TA extract for 24 hours. Moreover, phase-contrast microscopy of LnCaP cells after dose-dependent treatment with TA extract (67.5, 125, 250, and 500 µg/ml) for 24 hours reveals a prominent change in morphology of cells in treated cells compared to untreated control. The alteration in morphology was maximum at the higher doses of TA extract treatment (Fig. 1d).

We next intended to evaluate whether the TA extract induced antiproliferative effect in prostate cancer cells is due to apoptosis. To do so, we carried out a TUNEL assay. After the dose-dependent exposure of LnCaP cells to TA extract (67.5, 125, 250, and 500 µg/ml) for 24 hours, cells in all treatments including untreated control were incubated with a mixture of TdT and biotin-dUTP, followed by avidin-FITC for 30 minutes and nuclear staining (DAPI) in the dark. Our results showed that the number of TUNEL-positive cells increases as the treatment dose of TA extract increases (Fig. 2a). The maximum number of TUNEL-positive cells was observed 32% (*p < 0.05) when exposed to 500 µg/ml, followed by 11% (*p < 0.05) at 250 µg/ml, 7% (**)p < 0.01) at 125 µg/ml, and 5% (**)p < 0.01) at 67.5 µg/ml dose of TA extract compared to untreated control (Fig. 2b). Collectively, these results suggest that TA extract induces cell death of prostate cancer cells by apoptosis mechanism, and the effect is promising at higher doses of TA extract.

Additionally, we intended to evaluate whether the clonogenic property of prostate cancer cells was also attenuated using TA extract. Our results revealed that subtoxic doses of TA extract treatment lasting 24 hours significantly reduce the ability of LnCaP cells to form colonies at higher doses of TA extract when compared to untreated control. Further, the anticlonogenic

**Figure 2.** TA extract promotes apoptotic mode of cell death in prostate cancer (LnCaP) cells. (a) Visualization of TUNEL assay staining of apoptotic LnCaP cells after exposure to varying doses of TA extract (67.5, 125, 250, and 500 µg/ml) for 24 hours. (b) Histogram represents the percentage of TUNEL-positive cells after exposure to varying doses of TA extract (67.5, 125, 250, and 500 µg/ml) for 24 hours. The representation of data is the mean value of ±SE of three or more than three independent experiments with statistical significance equal to *p < 0.05 and **p < 0.01.
Effect of TA extract at a high concentration (250 µg/ml) was as good as that of positive control staurosporine (11.663 µg/ml) (Fig. 3a, b).

**TA extract abolishes migration, motility, and invasive property of prostate cancer (LnCaP) cells**

To evaluate whether TA extract could also abrogate the motility, migration, and invasive property of prostate malignant cells under *in vitro* settings, the antimetastatic activity after exposing LnCaP cells to TA extract was evaluated by the wound healing assay. Owing to the high percentage of cell death at higher doses of TA, the subtoxic doses (67.5, 125, and 250 µg/ml) of TA extract for 24 hours were intelligently selected to nullify any biased antimetastatic effect (Rah et al., 2012) at high dose (500 µg/ml) of TA extract when the antimotility evaluation was carried out on LnCaP cells. Our wound-healing results demonstrated a significant decline in cell migration and motility was observed when LnCaP cells were exposed to 125 and 250 µg/ml of TA extract (Fig. 4a, b) compared to untreated DMSO control, which was almost filled with cells migrated from adjacent areas. Further, the antimigration effect of 250 µg/ml of TA extract was statistically significant when compared to positive control camptothecin (2 µM).

To evaluate whether TA extract could have an inhibitory impact on the invasive property of prostate malignant cells, we carried out the Transwell Boyden chamber assay to determine whether TA extract attenuates the prostate cancer cell migration through the porous Matrigel membrane of the upper insert of the Transwell Boyden chamber. We observe that a substantial number of invasive cells fail to infiltrate via porous Matrigel membrane at higher doses of TA extract compared to untreated control (Fig. 5a). Additionally, our histogram analysis revealed that the number of invasive cells is 77, 58, and 28 at a dose of 67.5, 125, and 250 µg/ml of TA extract, respectively, when compared to 149 invasive prostate malignant cells in the untreated control (Fig. 5b). Further, the high dose (250 µg/ml) of TA extract attenuates invasion of prostate cancer (LnCaP) cells through the Matrigel membrane as effectively as that of positive control camptothecin (2 µM). Together, these findings demonstrate that TA extract inhibits the cellular motility, migration, and invasion of prostate cancer (LnCaP) cells significantly. Furthermore and equally importantly, the
Figure 4. TA extract abrogates the cell migration of prostate cancer cells. (a) Prostate cancer cells (LnCaP) were exposed to indicate concentrations of TA extract (67.5, 125, and 250 µg/ml) along with untreated control and positive control camptothecin (2 µM) for 24 hours to determine the motility of cells. The scale bar is 100 µm with 10× magnification. (b) The bar diagram represents the percentage of wound closure of prostate cancer (LnCaP) cells in control and in wells treated with varying doses of TA extract (67.5, 125, 250, and 500 µg/ml) for 24 hours. The representation of data is the mean value of ±SE of three or more than three independent experiments with statistical significance equal to **p < 0.01.

Figure 5. TA extract inhibits the cell invasion property of prostate cancer (LnCaP) cells. (a) LnCaP 2 × 10^5 cells were seeded in the upper insert of the Transwell Boyden chamber and simultaneously indicated that doses of TA extract (67.5, 125, 250, and 500 µg/ml) were added along with untreated control and positive control camptothecin (2 µM) for 24 hours to evaluate the anti-invasive potential of TA extract. The scale bar is 100 µm with 10× magnification. (b) The bar diagram represents the number of invaded prostate cancer (LnCaP) cells across the porous Matrigel membrane in control and in upper inserts treated with varying doses of TA extract (67.5, 125, 250, and 500 µg/ml) for 24 hours. The representation of data is the mean value of ±SE of three or more than three independent experiments with statistical significance equal to **p < 0.01.
antimetastatic activity of TA extract at a high dose is as effective as that of positive control camptothecin.

**TA Abrogates matrix metalloproteins MMP-2/9 activity as well as expression in prostate cancer (LnCaP) cells**

Further, we intended to evaluate whether TA extract could exhibit anti-MMPs activity secreted by LnCaP cells. We observe a prominent decrease in MMPs activity (MMP-2/9) by zymography in the conditional media samples collected after exposure to varying doses of TA extract for 24 hours. To evaluate whether TA extract downregulates the expression of MMPs at the translation level, we carried out immunoblotting of LnCaP cells exposed to varying doses of TA extract for 24 hours. Our immunoblotting results also revealed that there is a significant downregulation in the expression of MMP-2/9 proteins at higher doses of TA extract compared with untreated control. Together, these findings suggest that larger doses of TA effectively abrogate activity.

**TA extract exerts antimetastatic effect by modulating PI3K-Akt, and TGF-β pathways and their downstream targets in prostate cancer (LnCaP) cells**

We intended to explore whether TA extract could inhibit PI3K-Akt signaling in prostate cells. As displayed in Figure 7a, b, our Western blotting analysis of LnCaP cell lysates treated with varying doses (67.5, 125, 250, and 500 µg/ml) of TA extract inhibited phosphorylation of PI3K-P110α protein in a dose-dependent way. To evaluate whether the TA extract can also modulate the downstream mediators of PI3K-Akt signaling, our Western blotting results demonstrated a significant downregulation of phosphorylated p-Akt-Ser-473. This was evident when prostate malignant cells were exposed to higher doses of TA extract for 24 hours. Further, we did not observe any significant change in the expression of total Akt in the same samples. To explore whether TA extract could also attenuate the TGF-β-mediated epithelial-mesenchymal transition (EMT) associated metastasis in prostate cancer. We expose LnCaP cells to dose-dependent treatment of...
Figure 7. Modulation of PI3K-Akt signaling and its downstream targets by TA extract in prostate cancer cells. (a) Protein expression by Western blotting of prostate cancer (LnCaP) cells after treatment with varying doses of TA extract (67.5, 125, and 250 µg/ml) indicates the change in expression of PI3K-P110α, Akt, p-Akt-Ser473, and an internal control β-actin. (b) Fold change in protein expression of PI3K-P110α and p-Akt-Ser473 after being normalized with internal control β-actin by densitometry analysis. (c) Protein expression by Western blotting of prostate cancer (LnCaP) cells after treatment with varying doses of TA extract (67.5, 125, and 250 µg/ml) indicates the change in expression of TGF-β, SMAD2, SMAD3, and an internal control β-actin. (d) Fold change in protein expression of TGF-β, SMAD2, and SMAD3 after being normalized with an internal control β-actin by densitometry analysis. (e) Protein expression by Western blotting of prostate cancer cells (LnCaP) after treatment with varying doses of TA extract in the presence of untreated control indicates the change in expression of TIMP1, E-cadherin, snail, vimentin, and an internal control β-actin. (f) Fold change in protein expression of TIMP1, E-cadherin, snail, and vimentin after being normalized with internal control β-actin by densitometry analysis. The representation of data is the mean value of ±SE of three or more than three independent experiments with statistical significance equal to *p < 0.05; **p < 0.01.
TA extract (67.5, 125, 250, and 500 µg/ml) for 24 hours. Our immunoblotting results revealed that the TA extract downregulates the expression of TGF-β and its downstream mediators SMAD2 and SMAD3 in a dose-dependent manner (Fig. 7c, d). Further, to investigate whether TA extract-mediated downregulation of PI3K-Akt and TGF-β-SMAD2/3 signaling pathways could have any impact on MET, which are the key mediators in cell migration and invasion, we expose prostate malignant (LnCaP) cells to varying doses of TA extract (67.5, 125, 250, and 500 µg/ml) for 24 hours. Through immunoblotting experiments, we observe a prominent decline in the expression of MET proteins snail and vimentin with simultaneous induction in the protein expression of E-cadherin and TIMP1 at higher doses of TA extract (Fig. 7e, f). Together, these findings suggest that TA extract mitigates PI3K-Akt and TGF-β-SMAD2/3 stimulation and subsequently does not transmit a signal downstream associated proteins snail and vimentin that are regulating tumor cell invasion in prostate cancer cells.

DISCUSSION

Previous reports documented that numerous plant extracts exhibit an antiproliferative effect against a variety of tumor cell models (Kaur et al., 2009; Sreelatha et al., 2011). Our preliminary published work also revealed the inhibition of tumor cells (breast and colorectal) by TA extract (Alnuqaydan and Rah, 2020). TA displayed antitumor activity by modulating miRNA-1275 which plays a crucial role in the development of tumorigenesis (Shaalan et al., 2018). The current investigation discovered that TA extract promotes antiproliferative, anticlonogenic, antimigratory, and anti-invasive activity against prostate malignant cells. Mechanistically, TA extract modulates PI3K-Akt and TGF-β-SMAD2/3 signaling in prostate cancer cells for 24 hours. Further, TA extract downregulates its downstream signaling mediators MMP-2/9 and MET-associated proteins snail, vimentin with concomitant upregulation of TIMP1, and E-cadherin after treating cells for 24 hours. These observations revealed that TA extract could be the main source of promising anticancer agents to prevent prostate tumorigenesis in the future.

Numerous plants and derived products possess various phytochemicals that exhibit potential pharmacological properties such as anti-inflammatory, antidiabetic, and anticancer. Consequently, these plants and their derived products can act as a crucial source for drugs against various diseases, including cancer, with less deleterious effects on transformed normal cells (BPH cells) (Cassady et al., 1990). To date, approximately 50% of food and drug administration-approved drugs are directly extracted from either plants or their products (Patridge et al., 2016). The in vitro cellular models and preclinical studies have revealed that a significant number of plant species have still not been evaluated for their phytochemical characteristics, even though they potentially exhibit promising pharmacological activity with great efficacy and fewer toxicity issues. TA is one such plant from Saudi Arabia which has not been evaluated completely for its pharmacological analysis. However, there are some reports that TA extract displays some pharmacological activities such as anti-inflammatory, antioxidative, hepatoprotective, and antitumor activity in some tumor cell lines. The phytochemical analysis of the methanolic extract of TA by LC-MS analysis reveals the identification of some major compounds such as solenopsin, alanthone, dicumarol, dronabinol, oxymatrine, quercetin, resveratrol, and rottlerin (Supplementary Fig. 1; Supplementary Table 1) which exhibit anticancer properties such as immunomodulation, anti-inflammatory activity, antifertility activity, apoptosis and induction of autophagy, and ROS-mediated mitochondrial-dependent apoptosis to kill malignant cells.

Previous reports suggest that a mixture of phytochemicals in plant extracts exhibits a wide range of pharmacological activities due to the synergistic or additive effect of key phytochemicals in the extract (Effert, 2017; Kapinova et al., 2017; Phan et al., 2018; Rather et al., 2013). Consistent with these findings, the antiproliferative and antimetastatic activities of the TA extract are probably due to the synergistic interaction of major phytochemicals with other compounds in the extract. Our initial experiments demonstrated that TA extracts exhibit promising cytotoxic activity by significantly reducing the viability of prostate cancer cells. Additionally, we observed an incredibly low cytotoxic effect of TA extract at the same dose and time against normal BPH cells. Furthermore, we found that 50% of the cell populations of BPH cells were killed at a dose (IC50 = 9,541 µg/ml) by TA extract, which is a significantly much higher dose. Additionally, the antiproliferative activity of TA extract against a panel of prostate cancer cells was also supported by Brd U incorporation and trypan blue exclusion assays. The phase-contrast microscopy to analyze morphological changes further demonstrates the dose-dependent antiproliferative effect of TA extract. Additionally, our results suggest that TA extract has the potential for anticolony formation and can fight against prostate (LnCaP) cancer cells. Together, these findings demonstrate that TA extract has a promising antiproliferative effect that specifically promotes the death of prostate cancer cells and also possesses insignificant cytotoxicity against normal BPH cells with a safe toxicity profile.

Buranrat et al. (2020), revealed that Oroxyllum indicum extracts displayed promising antiproliferative effects against breast adenocarcinoma cells by modulating the expression of Rac1 signaling. Furthermore, the study reveals that downregulation of Rac1 expression abrogates adenocarcinoma cell migration and abolishes both MMP-9 activity and protein expression in breast cancer cells (Buranrat et al., 2020). A similar study revealed that a significant attenuation of hepatocyte growth factor-mediated cell invasion and migration of prostate cancer cells was observed in Boswellia frereana extract at higher doses. Furthermore, the analysis confirmed that B. frereana extract-mediated abrogation of prostate cell migration and invasion was due to modulation of e-Met signaling (Parr and Ali, 2018). The crucial step in metastasis is for the tumor cells to use a cascade of oncogenic mutations in order to invade or cross various physical barriers and spread to distant secondary sites (Björklund and Koivunen, 2005; Kumar and Weaver, 2009). Consistent with these previous studies, we observe that TA extract displays a considerable decrease in the cell motility of prostate cancer cells. To address any rational discrimination of TA extract in controlling the migration property of tumor cells with apoptosis, we carefully chose the concentrations of TA extract that are not lethal to cells. TUNEL assay results suggest that 125 µg/ml of TA extract does not promote significant cell death (7%), yet the same dose could modulate the migration of prostate cancer cells significantly to that of untreated control cells placed in a 6-well plate which was significantly occupied with
migrated cells. The striking feature of metastasis is the ability to disseminate malignant cells to distant secondary sites by crossing various physical barriers such as the extracellular basement matrix (Fares et al., 2020). Our results support the view that sublethal concentrations of TA extract considerably impede several tumor cells to display excellent antimigration properties against prostate cancer cells which possess the ability to infiltrate a perforated Matrigel-coated membrane.

Metastasis is a cascade of a complex process that includes cell invasion, motility migration, and last but not least, the activation and upregulation of MMPs. This functions to break the physical barrier in the form of the basement membrane and allow malignant cells to spread to distinct sites from the primary tumor site. Previous reports suggest that significantly high expression of MMPs has been implicated in metastasis (Dinicola et al., 2014; Hwang et al., 2006), and various herbal remedies are able to attenuate the expression as well as activity of matrix metalloproteinase. Consistent with these findings, our results revealed that a significant antimetastatic activity was displayed by TA extract against prostate malignant cells by abrogating both expression and activity of MMP-2/9 at the translational level, which plays an important role in metastasis.

Previous reports suggest that there is a strong correlation of deregulated PI3K-Akt signaling pathway activation due to frequent phosphatase and tensin homolog mutation in prostate cancer cells and performs a vital role in cell migration, invasion, and motility of malignant cells (Sarker et al., 2009; Shukla et al., 2007). Accumulating evidence demonstrates that aberrant PI3K-Akt-mediated signaling plays a crucial role in tumor cell growth. Recent reports suggest that the PI3K-Akt pathway-mediated cell migration and invasion in various types of solid malignancies to distant sites occurred through various downstream mediators (Altomare and Testa, 2005; Saji and Ringel, 2010). Moreover, recent reports suggest a strong correlation between the PI3K-Akt and associated signaling pathway with cancer cell migration, invasion, metastasis, and development of chemotherapeutic drug resistance (Singh et al., 2013; Vara et al., 2004). The PI3K-Akt pathway and its downstream mediators play a critical role in transferring and augmenting extracellular signaling to intracellular adapter proteins in prostate malignant cells and modulate cellular processes in favor of tumor growth (Rasool et al., 2016). In our study, we observe that TA extract downregulates the phosphorylation of the PI3K-Akt signaling pathway in prostate cancer cells. The TGF-β signaling pathway is well documented...
to play a critical role in tumorigenesis and metastasis (Katsuno et al., 2013). Previous reports suggest that TGF-β pathway regulates laminin, collagen, and fibronectin, and MMP-9 thereby modulates invasive and migratory ability of tumor cells (Margarant and Sonnenberg, 2010). The TGF-β signaling pathway plays a major role in EMT and metastasis of prostate cancers cells (Katsuno et al., 2013). Accumulating evidence revealed that various herbal medicines such as anthocyanidins, thyomoquinone, and curcumin abrogate EMT and attenuate metastasis by downregulating TGF-β-SMAD2/3 signaling (Kou et al., 2017; Zhang et al., 2016). Consistent with previous findings, our results revealed a dose-dependent downregulation of TGF-β-SMAD2/3 expression upon treatment of LnCaP cells with TA extract for 24 hours. Additionally, recent study revealed that various cytokine receptors such as TGF-β further augment the dysregulation of PI3K-Akt signaling, which in turn drives cells towards metastasis by pushing them towards EMT to MET (Jothimani et al., 2020). To evaluate whether TA extract could have any impact on these PI3K-Akt and TGF-β signaling pathways to curtail EMT to MET transition, we did immunoblotting of cell lysates after exposure to various doses of TA extract. Our results suggest that the higher doses of TA extract not only downregulate the phosphorylation status of PI3K-Akt or reduction in TGF-β-SMAD2/3 expression but also significantly abolish the expression of proteins which play a crucial role in tumor cell invasion, migration, and metastasis. Examples here include MMP-2/9 and MET-associated proteins snail and vimentin. Additionally, exposure of prostate malignant cells to higher doses of TA extract upregulates the protein expression of TIMP1 and E-cadherin, which regulated migration and invasion of cells in a quite different way to that of MET proteins. Together, our results infer that the TA extract promotes antimetastatic activity which includes antimotility, antimigration, and anti-invasion property against prostate malignant cells as displayed in schematic diagram in Figure 8. It does this by attenuating the hyperactivation of aberrant PI3K-Akt signaling and its downstream targets which plays a critical role in tumor metastasis.

CONCLUSION

Our findings, for the first time, revealed that TA extracts exhibit cytotoxic, anticlonogenic, and antimetastatic properties against prostate cancer cells. Mechanistically, TA extract downregulates the expression of PI3K-Akt and TGF-β-SMAD2/3 and its downstream target proteins MMP-2, MMP-9, and MET-associated proteins snail and vimentin, which play an important role in invasion and migration during the metastasis process. Additionally, we observe the upregulation of tight junction protein expression E-cadherin and TIMP1 in prostate cancer cells when exposed to higher doses of TA extract. We conclude that TA extract has potential anticancer properties that can fight prostate cancer cells. This should be evaluated in preclinical models in future studies to document its therapeutic potential against prostate cancer and other malignancies.

ACKNOWLEDGMENT

The authors would like to thank the Deanship of Scientific Research, Qassim University, for funding the publication of this project.

AUTHORS’ CONTRIBUTIONS


CONFLICT OF INTERESTS

The authors declare there is no conflict of interest.

ETHICAL APPROVAL

The current study does not involve experiments on animals or human subjects.

DATA AVAILABILITY

The study data is available with authors.

PUBLISHER’S NOTE

The current journal remains neutral with regard to jurisdictional claims in published institutional affiliation.

REFERENCES


How to cite this article:
## SUPPLEMENTARY TABLE

**Supplementary Table 1:** Phytochemicals detected from methanolic extract of TA by LC-MS

<table>
<thead>
<tr>
<th>S. No</th>
<th>M/Z</th>
<th>RT</th>
<th>Compound</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>103.08</td>
<td>6.447481</td>
<td>3-Methylbutanoic acid; 2-Methylbutyrate</td>
</tr>
<tr>
<td>2</td>
<td>104.04</td>
<td>0.781022</td>
<td>Pyruvate oxime</td>
</tr>
<tr>
<td>3</td>
<td>105.12</td>
<td>16.5714</td>
<td>Choline</td>
</tr>
<tr>
<td>4</td>
<td>107.04</td>
<td>22.75023</td>
<td>Aromatic aldehyde; D-Glycerate</td>
</tr>
<tr>
<td>5</td>
<td>108.96</td>
<td>24.27732</td>
<td>Bromoethane</td>
</tr>
<tr>
<td>6</td>
<td>119.04</td>
<td>11.48668</td>
<td>Succinic acid</td>
</tr>
<tr>
<td>7</td>
<td>126.120003</td>
<td>1.72972046</td>
<td>Gamma-Coniceine</td>
</tr>
<tr>
<td>8</td>
<td>128.04</td>
<td>24.26456</td>
<td>5-Amino-4-imidazole carboxylate; 1-Methyl-4-nitroimidazole</td>
</tr>
<tr>
<td>9</td>
<td>130.08002</td>
<td>0.79923889</td>
<td>L-Pipeolate</td>
</tr>
<tr>
<td>10</td>
<td>131.04</td>
<td>6.248767</td>
<td>Itaconate; (E)-Glutaconate</td>
</tr>
<tr>
<td>11</td>
<td>133.08</td>
<td>20.91498</td>
<td>(R)-2-Hydroxyisocaproate; 6-Hydroxyhexanoic acid</td>
</tr>
<tr>
<td>12</td>
<td>134.04</td>
<td>6.839831</td>
<td>L-Aspartate</td>
</tr>
<tr>
<td>13</td>
<td>135.12</td>
<td>24.28927</td>
<td>P-Cymene</td>
</tr>
<tr>
<td>14</td>
<td>136.08</td>
<td>8.631082</td>
<td>2-Phenylacetamide</td>
</tr>
<tr>
<td>15</td>
<td>137.04</td>
<td>15.86743</td>
<td>Hypoxanthine; Threonate</td>
</tr>
<tr>
<td>16</td>
<td>139.08</td>
<td>6.450736</td>
<td>4-Hydroxyphenylethanol; Styrene-cis-2,3-dihydropiol</td>
</tr>
<tr>
<td>17</td>
<td>140.039993</td>
<td>7.61881435</td>
<td>4-Nitrophenol; 2-Nitrophenol; 3-Nitrophenol; 3-Hydroxypicolinic acid</td>
</tr>
<tr>
<td>18</td>
<td>142.08</td>
<td>8.676849</td>
<td>Hypoglycin; Arecaidine</td>
</tr>
<tr>
<td>19</td>
<td>145.08</td>
<td>13.84979</td>
<td>trans-4-Hydroxycyclohexanecarboxylate</td>
</tr>
<tr>
<td>20</td>
<td>146.039993</td>
<td>0.78391111</td>
<td>alpha-Ketoglutarate</td>
</tr>
<tr>
<td>21</td>
<td>146.16</td>
<td>0.787356</td>
<td>Spermidine</td>
</tr>
<tr>
<td>22</td>
<td>147</td>
<td>5.374421</td>
<td>Fluopropanate</td>
</tr>
<tr>
<td>23</td>
<td>147.12</td>
<td>13.21838</td>
<td>L-Lysine</td>
</tr>
<tr>
<td>24</td>
<td>149.04</td>
<td>22.59839</td>
<td>D-Arabinono-1,4-lactone</td>
</tr>
<tr>
<td>25</td>
<td>151.08</td>
<td>4.124735</td>
<td>Tolylacetate</td>
</tr>
<tr>
<td>26</td>
<td>160.08002</td>
<td>0.81778333</td>
<td>Indole-3-acetaldehyde</td>
</tr>
<tr>
<td>27</td>
<td>161.039993</td>
<td>17.291544</td>
<td>2-Oxoadipate</td>
</tr>
<tr>
<td>28</td>
<td>162.119995</td>
<td>6.89406976</td>
<td>L-Carnitine</td>
</tr>
<tr>
<td>29</td>
<td>163.08</td>
<td>24.28231</td>
<td>Methyl cinnamate; Safrole</td>
</tr>
<tr>
<td>30</td>
<td>165.12</td>
<td>24.2979</td>
<td>Jascone</td>
</tr>
<tr>
<td>31</td>
<td>189.12</td>
<td>11.11041</td>
<td>Glycyl-leucine</td>
</tr>
<tr>
<td>32</td>
<td>167.16</td>
<td>5.766924</td>
<td>Robinobiose</td>
</tr>
<tr>
<td>33</td>
<td>175.08</td>
<td>22.49876</td>
<td>N-Formimino-L-glutamate</td>
</tr>
<tr>
<td>34</td>
<td>177</td>
<td>9.841988</td>
<td>3-Chloro-cis,cis-muconate</td>
</tr>
<tr>
<td>35</td>
<td>178.08002</td>
<td>9.75604286</td>
<td>4-Hydroxy-4-methylglutamate</td>
</tr>
<tr>
<td>36</td>
<td>177.12</td>
<td>10.12313</td>
<td>L-Cladinoside; Metaldehyde</td>
</tr>
<tr>
<td>37</td>
<td>181.08</td>
<td>8.720061</td>
<td>D-Glucose</td>
</tr>
<tr>
<td>38</td>
<td>189.119995</td>
<td>11.1007144</td>
<td>Glycyl-leucine</td>
</tr>
<tr>
<td>39</td>
<td>193.080002</td>
<td>5.79943623</td>
<td>Carapin; Myristin</td>
</tr>
<tr>
<td>40</td>
<td>197.160004</td>
<td>8.60402733</td>
<td>Linalyl acetate; alpha-Terpiny acetate</td>
</tr>
<tr>
<td>41</td>
<td>199.08</td>
<td>7.810947</td>
<td>L-Mimosine</td>
</tr>
<tr>
<td>42</td>
<td>205.199997</td>
<td>9.61738333</td>
<td>beta-Caryophyllene</td>
</tr>
<tr>
<td>43</td>
<td>207</td>
<td>26.1537176</td>
<td>Chloroneb</td>
</tr>
</tbody>
</table>
SUPPLEMENTARY FIGURE

1. Solenopsin A

2. Ailanthone
3. Dicumarol

4. Dronabinol
5. Oxymatrine

6. Quercetin
7. Resveratrol

![Resveratrol Mass Spectrum]

8. Rottlerin

![Rottlerin Mass Spectrum]